Alnylam Pharmaceuticals, Inc.
$239.56
Market Cap
$32.06B
Shares Outstanding
133.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 28, 2004
Round Lot
40
Locale
US
Day Open
$246.41
Day High
$246.49
Day Low
$238.51
Volume
2.76M
VWAP
$240.85
Prev Close
$245.51
Transactions
--
Acc. Volume
--
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Alnylam Pharmaceuticals, Inc. (ALNY) closed the 2026-09-18 session at $239.56, down 2.42% versus the previous close (-5.95). The stock opened at $246.41 and traded between $238.51 and $246.49 during that session. Session trading volume was 2.8M shares. The volume-weighted average price (VWAP) is $240.85.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Alnylam Pharmaceuticals, Inc. has a market capitalization of $32.06 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ALNY is listed on the XNAS exchange. The company employs approximately 2,500 people. Alnylam Pharmaceuticals, Inc. is headquartered in CAMBRIDGE, MA. The recorded listing date is 2004-05-28.
On this page you can find market ALNY stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.